Outcome of advanced, unresectable conventional central chondrosarcoma.

摘要: BACKGROUND For patients who have chondrosarcoma with unresectable disease, because of tumor location, size, or extensive metastatic treatment options are very limited their relative resistance to radiotherapy and chemotherapy. The overall survival this patient population is poor; however, specific studies lacking, large series not been published. Therefore, the authors conducted retrospective, 2-center study gain insight into outcome advanced, unresectable, conventional central chondrosarcoma. METHODS All were diagnosed between January 1, 1980 December 31, 2011 in 2 major European bone sarcoma centers (Rizzoli Institute, Bologna, Italy Leiden University Medical Center, Leiden, Netherlands) selected. Relevant information was collected from medical records at both centers. RESULTS In total, 171 met selection criteria. rate for all 48% 1 year, 24% years, 12% 3 6% 4 2% 5 years. Patients locally advanced disease without distant metastases had a significantly better than (P = .0014). Systemic treatment, consisting either doxorubicin-based chemotherapy noncytotoxic drugs imatinib sirolimus, improved compared no (P = .0487). For metastases, associated benefit (P = .0032). CONCLUSIONS This provides standard rates after diagnosis chondrosarcoma. may improve survival, although bias retrospective nature influenced outcome. poor underlines need new therapeutic population. Cancer 2014;120:3159–3164. © 2014 American Society.